Email Facebook Twitter

RNS EXCLUSIVE: Cabot praise 3D seismic mapping after successful winter programme

Regulatory News

Scrip Dividend - total issued shares

Thu, 5th Oct 2017 07:00

RNS Number : 7408S
ConvaTec Group PLC
05 October 2017


Scrip Dividend - total issued shares



Reading, United Kingdom (5 October 2017)

On 3 August 2017 ConvaTec Group Plc ("ConvaTec" or "the Company")  declared an interim dividend of 1.4 cents per share (the "interim dividend"). This interim dividend is to be paid on 20 October 2017 to shareholders on the share register as at 8 September 2017 ("record date"). The dividend is payable in cash in sterling to holders of ordinary shares. On 11 September 2017 the Company announced that a scrip dividend scheme will be made available for this interim dividend allowing shareholders to elect to receive their dividend in the form of new ordinary shares. The calculation price for the scrip dividend scheme was announced on 14 September.

It is confirmed that 377,948 ordinary shares of 10 pence each will be allotted and issued on 20 October 2017 by the Company to those shareholders who elected to receive the scrip dividend alternative. The shares will rank pari passu with the existing issued ordinary shares of the Company. Application will be made to the Financial Conduct Authority for the shares to be admitted to the Official List and to the London Stock Exchange for the shares to be admitted to trading.

Dealings in the share issued under the scrip dividend scheme is expected to commence on 20 October 2017.


Key dates in respect of the scrip dividend scheme for the interim dividend are:

Ex-dividend Date

7 September 2017

Record Date

8 September 2017

Scrip calculation price determined

7-13 September 2017 (inclusive)

Scrip calculation price available and announced

14 September 2017

Mandate delivery deadline for Shares held in uncertificated form

3.00 p.m. on 29 September 2017

Mandate delivery deadline for Shares held in certificated form

5.00 p.m. on 29 September 2017

Announcement of the total amount of new shares to be issued

5 October 2017

Dividend payment date

20 October 2017

Dispatch of statement in accordance with section 7 of Scheme Rules and share certificates, CREST accounts credited/updated, and first day of dealings in New Shares

20 October 2017






Bobby Leach, VP Group Corporate Affairs, ConvaTec                    +44 (0)7770 842 226

Alastair Elwen, Finsbury                                                             +44 (0)207 251 3801

Analysts and Investors


John Crosse, VP Investor Relations, ConvaTec                             +44 (0)7500 141 435

Kirsty Law, Director Investor Relations, ConvaTec                         +44 (0)7470 909 582


Legal Entity Identifier Code   213800LS272L4FIDOH92


About ConvaTec


ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit where a copy of this announcement can also be found.



# # #


This information is provided by RNS
The company news service from the London Stock Exchange

Related Shares:
Convatec Group (CTEC)

Back to Regulatory News

Share Price, Share Chat, Stock Market news at
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.